Promoting research partnerships to improve veterans’ health

NAVREF is proud to recognize Cohen Veterans Bioscience as our Champion Sponsor

NAVREF News Center

  • 25 Jul 2019 9:29 AM | Hawk Tran (Administrator)

    The FY19 Defense Appropriation provides $125 million (M) to the Department of Defense Psychology Health/Traumatic Brain Injury Research Program (PH/TBIRP) to support critical psychological health (PH) - and traumatic brain injury (TBI)-related research and development efforts to benefit Service members, Veterans, and other beneficiaries of the military health system. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The U.S. Army Medical Research and Materiel Command (USAMRMC) Congressionally Directed Medical Research Programs (CDMRP) provides execution management support for DHA research program areas, including the Joint Program Committee-8/Clinical and Rehabilitative Medicine Research Program (JPC-8/CRMRP). The managing agent for this Program Announcement is the CDMRP with strategic oversight from the JPC-8/CRMRP.

    The JPC-8/CRMRP seeks to implement long-term strategies to develop knowledge and materiel products to reconstruct, rehabilitate, and provide definitive care for injured Service members.  The ultimate goal is to return Service members to duty and improve their quality of life. FY19 PH/TBIRP Complex TBI Rehabilitation Research (CTRR) Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov.

    https://cdmrp.army.mil/funding/phtbi

    CTRR – Clinical Research Award (CTRR-CRA) – Preproposal due September 10, 2019

    Independent investigators at all academic levels (or equivalent)

    • Supports applied and translational research to advance the development of knowledge and materiel products for rehabilitation and restoration of function following traumatic brain injury (TBI).
    • Supported research can include preclinical studies using human subjects or samples and observational or mechanistic clinical research studies.
    • Supported research should investigate effectiveness of rehabilitation in remediating post-concussive sequelae across the spectrum of known post-concussive vulnerabilities.
    • Clinical trials are not allowed.
    • Preclinical research using animals is not allowed.
    • Must address one or more FY19 PH/TBIRP CTRR Areas of Emphasis.
    • Preproposal submission is required; application submission is by invitation only.
    • Maximum funding of $2.0M for total costs (direct plus indirect costs).
    • Maximum period of performance is 3 years.

    CTRR – Clinical Trial Award (CTRR-CTA) – Preproposal due September 10, 2019

    Independent investigators at all academic levels (or equivalent)

    • Supports clinical trials to validate existing complex mild TBI (mTBI) rehabilitation interventions and practice patterns in Department of Defense and Department of Veterans Affairs rehabilitation facilities.
    • Supported clinical trials should measure the effect of the intervention as well as measure the effectiveness of standard-of-care practices in remediating post mTBI sequelae across the spectrum of known functional vulnerabilities.
    • Encourages clinical trials that identify determinants of successful recovery, return to duty/work, functional restoration, and objective brain function measurement(s) following mTBI.
    • Preclinical studies are not allowed.
    • Preproposal submission is required; application submission is by invitation only.
    • Maximum funding of $4.0M for total costs (direct plus indirect costs),
    • Maximum period of performance is 3 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcement and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PH/TBIRP, or other CDMRP-administered programs, please visit the CDMRP (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 25 Jul 2019 9:27 AM | Hawk Tran (Administrator)

    The FY19 Defense Appropriation provides $15 million (M) to the Department of Defense Combat Readiness – Medical Research Program (CRRP) to support military-relevant advanced technology and therapeutic research related to forward-deployable solutions that can promptly address life-threatening injuries, medical threats, and treatments for Service members in current and future battlefield settings.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Broad Agency Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The Congressional language for the CRRP encompasses research that would enable the Warfighter to better respond to serious injury, as well as solutions to mitigate the long-term effects of battlefield trauma.  The CRRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 CRRP Broad Agency Announcement and General Submission Instructions for the following award mechanism are anticipated to be posted on the Grants.gov website in August 2019.  Pre-application and application deadlines will be available when the Broad Agency Announcement is released.  This pre-announcement should not be construed as an obligation by the Government.

    FY19 CRRP will solicit research applications addressing at least one of the Focus Areas described below.  The Focus Areas broadly describe current needs to ensure readiness for delivering front-line care in combat situations, and for delivering medical damage control capability, assets, and life-saving interventions to address the emerging needs of the Warfighter and Service medics during prolonged and en route care in austere and combat environments, including the acute and early management of combat-related trauma at the point of injury.

    Applications submitted to the FY19 CRRP must address at least one of the following four Focus Areas:

    • Scalable solutions for wound care that can address prevention of bleeding, infection, and acute pain; delivery of therapeutics (including non-opioid solutions for pain); and promotion of healing
    • Decision-support solutions, such as algorithms, artificial intelligence, deep learning, and/or telemedicine, for triage and management of severely injured Warfighters, to include management and monitoring of:

    o   Hemorrhage and resuscitation (i.e., airway management, control of bleeding, sedation, etc.)

    o   Acute pain

    o   Multi-casualty events when delayed evacuation exceeds available capability and/or capacity, in order to extend provider capabilities

    • Solutions that address hemorrhage control, including:

    o   Non-compressible torso hemorrhage

    o   Alternatives to optimize logistics and administration of blood products to the Warfighter

    • Wearable sensors with broader multiple capabilities to identify and monitor medical management of injuries, to include:

    o   Environmental exposures

    o   Onset of infection, including sepsis

    o   Physiological status (heart rate, blood pressure, respiration), stress monitoring tools

    o   Neurological injury

    o   Point-of-care imaging

    Additional concurrent research approaches that address mitigation of long-term physical and psychological complications that occur from poor management of trauma pain and trauma care, as well as treatments for sepsis and new therapies for multidrug-resistant pathogens, including applications to sepsis, wound care, and injuries incurred outside the battlefield are encouraged, but not required.

    https://cdmrp.army.mil/pubs/press/2019/19crrppreann

    Rapid Development and Translational Research Award

    • Extramural applicants only
    • Independent investigators at all academic levels (or equivalent)
    • Preproposal in the form of a Letter of Intent is required.
    • Supports research that will accelerate the movement of promising ideas into clinical applications, including healthcare products, technologies, and/or practice guidelines.
    • Preclinical research, including animal studies, that is already supported by substantial preliminary or published data and strongly validates clinical translation is appropriate.
    • Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed.
    • Maximum funding of $1,500,000 for direct costs (plus indirect costs)
    • Maximum period of performance is years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.orgprior to the pre-application deadline.  All applications must conform to the final Broad Agency Announcement and General Submission Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Broad Agency Announcement is released.  For email notification when Broad Agency Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the CRRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 17 Jul 2019 8:22 AM | Hawk Tran (Administrator)

    The FY19 Defense Appropriation provides $125 million (M) to the Department of Defense Psychological Health and Traumatic Brain Injury Research Program (PHTBIRP) to support specific Defense Health Agency (DHA) J9 Research and Development Directorate program areas, including Joint Program Committee-5/Military Operational Medicine Research Program (JPC-5/MOMRP).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the DHA J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The FY19 PHTBIRP Program Announcement and General Application Instructions for the following award mechanism are posted on the Grants.gov website.

    https://cdmrp.army.mil/funding/phtbi

    Prevention Research to Reduce Sexual Assault and/or Understand Adjustment Disorders (PSAAD) – Letter of Intent Due September 19, 2019

    Investigators at all academic levels are eligible to be names as a Principal Investigator on the application.

    • The PSAAD IIFRA is intended to support research focused on (1) development or adaptation of prevention efforts to reduce the occurrence of sexual assault and/or harassment and/or (2) understanding the diagnosis, assessment, and screening of adjustment disorders as a consequence of sexual assault and/or stressors that precipitate adjustment disorders.
    • All applications must address at least one of the PSAAD IIFRA Focus Areas and be of clear scientific merit with direct relevance to military and public health.
    • Research involving human subjects is permitted; however, this award may not be used to conduct clinical trials.
    • Preclinical research using animals is not permitted.
    • This funding opportunity is not focused on Veterans.
    • Submission of a Letter of Intent is required.
    • Maximum funding of $750K for direct costs (includes direct and indirect costs).
    • Maximum period of performance is 3 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PHTBIRP or other CDMRP-administered and supported programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org


  • 3 Jul 2019 10:14 AM | Hawk Tran (Administrator)

    The FY19 Defense Appropriation provides $10 million (M) to the Department of Defense Chronic Pain Management Research Program (CPMRP) to support research of exceptional scientific merit with the potential to make a significant impact on improving the health and quality of life of Service members, Veterans, and all Americans living with chronic pain.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).The CPMRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 CPMRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in July 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    Per the FY19 CPMRP Congressional appropriation, chronic pain is defined as a pain that occurs on at least half the days for six months or more, and which can be caused by issues including, but not limited to:  combat- and training-related physical or mental stress and trauma, migraines and chronic headaches, traumatic brain injury, arthritis, muscular-skeletal conditions, neurological disease, tick and vector-borne disease, other insect-transmitted or tropical disease, and cancer.  The CPMRP seeks to support and promote innovative, high-impact research to prevent the development and improve the management of chronic pain, with specific emphasis on the utilization and implementation of non-opioid therapies or non-addictive complementary methods.  Applications from investigators within the military Services and applications involving multidisciplinary collaborations among academia, industry, the military Services, the U.S. Department of Veterans Affairs (VA), and other Federal Government agencies are highly encouraged.

    For FY19, the CPMRP Focus Areas will be required.  Each award mechanism (listed below) will require at least one of the FY19 CPMRP Focus Areas as indicated in the table.

    Award Mechanism

    FY19 Focus Area

    Investigator-Initiated Research Award

    “Chronification” of Pain (i.e., the acute-to-chronic pain transition)

    Translational Research Award

    Comparative Effectiveness

    Translational Research Award

    Implementation Science (evidence-based, efficacious interventions to manage chronic pain)

    https://cdmrp.army.mil/pubs/press/2019/19cpmrppreann

    Investigator-Initiated Research Award

    Investigators at or above the level of Assistant Professor (or equivalent)

    ·      Emphasis on innovative and impactful research

    ·      Applications must include preliminary and/or published data or clinical observations that originated from the research team that support the rationale for the proposed study.

    ·      Should be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

    ·      Multidisciplinary collaborations are encouraged.

    ·      Clinical trials are not allowed.

    ·      Maximum funding of $900,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is years

    Translational Research Award

    Investigators at or above the level of Assistant Professor (or equivalent)

    ·      Supports acceleration of evidence-based ideas and research into clinical applications (e.g., healthcare products, technologies, practice guidelines).

    ·      Applications must include preliminary and/or published data collected by the research team that support the rationale for the proposed study.

    ·      Effectiveness-implementation hybrid type 2 and type 3 studies are encouraged.

    ·      Projects may include studies using prospective human subject enrollment or retrospective data analysis; limited clinical studies are allowed.

    ·      Animal studies are not allowed.

    ·      Maximum funding of $1,400,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is 4 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the CPMRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 28 Jun 2019 11:10 AM | Hawk Tran (Administrator)

    The FY19 Defense Appropriation provides $10 million (M) to the Department of Defense (DoD) Melanoma Research Program (MRP)to support innovative, high-impact melanoma research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    FY19 MRP Program Announcements and General Application Instructions for the following award mechanism is posted on the Grants.gov website. 

    The FY19 MRP Focus Areas are listed below:

    • Precursor Lesions, Melanomagenesis, Host Factors, and the Tumor Microenvironment (e.g., melanoma instigators, ultraviolet [UV] exposure, other instigators)
    • Melanoma Primary Tumor Evolution (e.g., dormancy, heterogeneity, metabolism, epigenetic dysregulation, cell death)
    • Therapeutic Prevention
    • Minimal Residual Disease
    • Rare Melanomas (e.g., uveal, acral, leptomeningeal disease, pediatric, adolescent and young adult [AYA], mucosal)

    The MRP challenges the research community to redefine the concept of prevention and has issued a FY19 MRP Challenge Statement that should be considered when responding to the FY19 MRP Focus Areas and funding opportunities.

    https://cdmrp.army.mil/funding/mrp

    Concept Award – Letter of Intent due October 2, 2019

    Investigators at or above postdoctoral fellow (or equivalent)

    ·      Supports the exploration of highly innovative, untested, potentially groundbreaking concepts in melanoma.

    ·      Emphasis is on Innovation.

    ·      Preliminary data is strongly discouraged.

    ·      Clinical trials are not allowed.

    ·      Blinded review.

    ·      The maximum allowable funding for the entire period of performance is $75,000 in direct costs.

    ·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    ·      The maximum period of performance is year.

    A pre-application (letter of intent or pre-proposal) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the MRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507

    help@eBrap.org


  • 26 Jun 2019 1:51 PM | Hawk Tran (Administrator)

    The FY19 Defense Appropriation provides $125 million (M) to the Department of Defense Psychology Health/Traumatic Brain Injury Research Program (PH/TBIRP) to support critical psychological health (PH) - and traumatic brain injury (TBI)-related research and development efforts to benefit Service members, Veterans, and other beneficiaries of the military health system. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The U.S. Army Medical Research and Materiel Command (USAMRMC) Congressionally Directed Medical Research Programs (CDMRP) provides execution management support for DHA research program areas, including the Joint Program Committee-8/Clinical and Rehabilitative Medicine Research Program (JPC-8/CRMRP). The managing agent for this Program Announcement is the CDMRP with strategic oversight from the JPC-8/CRMRP.

    The JPC-8/CRMRP seeks to implement long-term strategies to develop knowledge and materiel products to reconstruct, rehabilitate, and provide definitive care for injured Service members.  The ultimate goal is to return Service members to duty and improve their quality of life. The PH/TBIRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY19 PH/TBIRP Complex TBI Rehabilitation Research (CTRR) Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in July 2019. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.

    FY19 PH/TBIRP will solicit research applications for the following CTRR Areas of Emphasis (all three bulleted areas are for CRA; only 2nd and 3rd areas are for CTA):

    • ·       Return to Duty (RTD) Risk Assessment; Computational Model Development or Validation
    • Integrate objective mild TBI (mTBI) patient data from multiple domains through computational modeling to inform RTD capability 
    • Clinical support tool leveraging computational modeling to measure and communicate risk associated with returning injured warfighters to duty following mTBI
    • ·       Determination of the Objective Outcome Measures of Brain Impairment after mTBI with Existing FDA cleared Devices
    • Develop objective measure(s) of brain function that determine severity of functional impairment
    • Correlate brain function to RTD performance
    • ·       Optimization of Treatment Strategy based on Patient Classification to improve management of patients with mTBI as described above
    • Determine indicators of successful recovery following mTBI
    • Validate algorithms for multi-modal treatment strategies

    Projects focused on other research areas relevant to the intent of the CTRR-CRA may be submitted for consideration, provided that sufficient justification is included in the application.

    https://cdmrp.army.mil/pubs/press/2019/19phtbipreann_ctrr

    CTRR – Clinical Research Award (CTRR-CRA)

    Independent investigators at all academic levels (or equivalent)

    • Supports applied and translational research to advance the development of knowledge and materiel products for rehabilitation and restoration of function following TBI.
    • Supported research can include preclinical studies using human subjects or samples and observational or mechanistic clinical research studies.
    • Clinical trials are not allowed.
    • Preclinical research using animals is not allowed.
    • Must address one or more FY19 PH/TBIRP CTRR Areas of Emphasis.
    • Preproposal is required; application submission is by invitation only.
    • Maximum funding of $2.0M for total costs (direct plus indirect costs).
    • Maximum period of performance is 3 years.

    CTRR – Clinical Trial Award (CTRR-CTA)

    Independent investigators at all academic levels (or equivalent)

    • Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, Phase 0), to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.
    • Interventions should be limited, existing, and manualized. Studies may include seeking to optimize dosing in existing interventions.
    • Preclinical studies are not allowed.
    • Must address one or more FY19 PH/TBIRP CTRR Areas of Emphasis.
    • Preproposal is required; application submission is by invitation only.
    • Maximum funding of $4.0M for total costs (direct plus indirect costs),
    • Maximum period of performance is 3 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcement and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcement is released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PH/TBIRP, or other CDMRP-administered programs, please visit the CDMRP (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 25 Jun 2019 9:23 AM | Hawk Tran (Administrator)

    The FY19 Defense Appropriation provides $20 million (M) to the Department of Defense Joint Program Committee 8/Clinical and Rehabilitative Medicine Research Program (JPC-8/CRMRP) to support the development of regenerative medicine solutions and technical capabilities that repair, reconstruct, or regenerate tissue lost or damage due to traumatic injury through collaborative partnerships and synergistic projects that inform and build on each other.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The JPC-8/CRMRP is offering the Regenerative Medicine Focused Research Award (RMFRA) as its next iteration of the Armed Forces Institute of Regenerative Medicine (AFIRM), AFIRM III, in FY19 to continue its effort to support the development of regenerative medicine solutions.  The FY19 JPC-8/CRMRP Program Announcement and General Application Instructions for the RMRFA mechanism are posted on the Grants.gov website. 

    Focus Areas and Areas of Encouragement

    All projects submitted under the FY19 JPC-8/CRMRP RMFRA will be required to address one or both of the following Focus Areas:

    • Peripheral nerve regeneration
    • Skeletal muscle regeneration

    Efforts to regenerate peripheral nerve should focus on restoring maximal function; the goal should be accelerating functional recovery and/or reducing the need for autograft; efforts should not simply address metrics of nerve regrowth or conduits to cross nerve gaps.  Similarly efforts to regenerate skeletal muscle should extend beyond restoration of muscle bulk or structure and address restoration of maximal muscle function.  The FY19 JPC-8/CRMRP RMFRA Areas of Encouragement include:

    • Immediate reconnection of severed peripheral nerves (e.g., preventing Wallerian degeneration)
    • Regeneration of composite muscle and nerve injuries leading to improved function
    • Regenerative therapies for volumetric muscle loss
    • Preservation of denervated end organs
    • Maintenance of the motor end plate or regeneration of the neuromuscular junction
    • Improving the rate of peripheral nerve regeneration

    https://cdmrp.army.mil/funding/jpc8

    Regenerative Medicine Focused Research Award (RMFRA) – Preproposal due August 7, 2019

    Independent investigators at all academic levels (or equivalent)

    ·      Preproposal is required; full application submission is by invitation only.

    ·      Accommodates either Single Principal Investigator (PI) or Multiple PI submissions.  All research teams should include highly qualified investigators. Partnerships should include multidisciplinary investigators that bring resources and expertise that combine to create a robust, synergistic collaboration.

    ·      Supports the development of regenerative medicine technical capabilities and solutions through collaborative partnerships and synergistic projects (Multiple PI submissions) or through comprehensive projects (Single PI submissions) to accelerate regenerative medicine solutions and technical capabilities that repair, reconstruct, or regenerate tissue lost or damaged due to traumatic injury

    ·      Multi-institutional collaborations between/among academia, industry, and Department of Defense and/or Department of Veterans Affairs facilities are highly encouraged.

    ·      Research projects should be either advanced preclinical research or early stage clinical trials (Phase 0, I, or IIa)

    ·      Applications must address one or both of the FY19 Joint Program Committee 8/CRMRP RMFRA Focus Areas

    ·     Maximum funding of $10 million (M) for total costs (direct plus indirect costs).

    ·     Submissions may range in size and scope as appropriate for the work proposed, and will be equally considered.  Submissions with a total of less than the maximum  of $10M are encouraged

    ·     Maximum period of performance is 5 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcement and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the JPC-8/CRMRP, please visit the CRMRP website (https://crmrp.amedd.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org

                                                       

    www.facebook.com/TheCDMRP


  • 24 Jun 2019 10:22 AM | Hawk Tran (Administrator)

    The FY19 Defense Appropriation provides $20 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP)to support research of exceptional scientific merit in the area of kidney cancer.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    FY19 KCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

    https://cdmrp.army.mil/funding/kcrp

    Academy of Kidney Cancer Investigators - Dean Award – Letter of Intent due September 17, 2019

    Dean must be an established kidney cancer researcher.

    ·      Supports visionary individuals who are established kidney cancer researchers with a strong record of mentoring and commitment to leadership.

    ·      Academy Dean will oversee an interactive virtual academy of Early-Career Investigators and their designated mentors, facilitate regular interactive communication among all Academy members, and assess the research progress and career progression of the Early-Career Investigators.

    ·     Maximum funding of $625,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance 5 years.

    ·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    Academy of Kidney Cancer Investigators - Early Career Investigator Award – Letter of Intent due September 17, 2019

    Must be within 3 years of his/her last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent as of full application submission deadline.

    Letter attesting to eligibility required.

    ·      Supports addition of new Early-Career Investigators to the unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty.

    ·      Early-Career Investigators whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.

    ·      A Designated Mentor who is an experienced kidney cancer researcher with kidney cancer funding is required.

    ·      The Designated Mentor not required to be at the same institution as the Early-Career Investigator.

    ·      Preliminary data required.

    ·      Clinical trials are not allowed.

    ·     Maximum funding of $725,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance 4 years.

    ·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    Clinical Consortia Award – Letter of Intent due September 17, 2019

    Independent Investigators at or above the level of Assistant Professor (or equivalent)

    ·      Supports development of a consortium that will facilitate rapid execution of collaborative clinical trials that will bring to market high-impact, novel therapeutics that will ultimately and significantly decrease the impact of kidney cancer.

    ·      Funds may not be used for research or development of clinical protocols.

    ·      Trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer encouraged.

    ·      One Coordinating Center and three clinical trial sites will be selected and be jointly responsible for proposing, selecting, and conducting trials.

    ·      Sites must provide plans for accruing patients from populations disproportionately affected by kidney cancer

    ·      Consortium expected to achieve financial self-sufficiency, such that operations can continue after the award ends.

    ·      The consortium is expected to achieve financial self-sufficiency, such that operations can continue after the award period ends.

    Coordinating Center:

    ·      Maximum funding of $3M for direct costs (plus indirect costs).

    ·     Maximum period of performance is 3 years.

    ·     Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    Clinical Trial Sites:

    ·     Maximum funding of $600,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 3 years.

    ·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 24 Jun 2019 10:21 AM | Hawk Tran (Administrator)

    The FY19 Defense Appropriation provides $10 million (M) to the Department of Defense Orthotics and Prosthetics Outcomes Research Program (OPORP) to support research that evaluates the comparative effectiveness of orthotic and prosthetic clinical interventions using patient-centric outcomes for Service members and Veterans who have undergone limb amputation.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    FY19 OPORP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

    OPORP awards are focused on outcomes-based best practices through analysis of the merits of prosthetic and orthotic device options currently available, not on the development of new or the improvement of existing technology.  The intent of the awards is to generate clinically useful evidence that will enhance and optimize patient outcomes.

    Focus Areas:  The OPORP will only consider applications that specifically address the critical needs of the orthotics and prosthetics outcomes research community in one or more of the FY19 Focus Areas.  The OPORP will solicit research applications that address at least one of the following FY19 Focus Areas:

    • Orthotic or Prosthetic Device Form:  Understand patient outcomes through the analysis and characterization of variables related to the form of currently available clinical options such as device size, shape, material, and/or configurations.
    • Orthotic or Prosthetic Device Fit:  Understand patient outcomes related to human-device interface and component connection through the analysis of variables in currently available clinical options that facilitate fit-related metrics such as comfort and/or usability.
    • Orthotic or Prosthetic Device Function:  Understand patient outcomes through the analysis of variables related to currently available device function such as device control, sensors, and passive or active response with respect to activities of daily living and other real-world activities.

    https://cdmrp.army.mil/funding/oporp

    Clinical Research Award – Letter of Intent due July 24 2019

    Independent investigators at all academic levels (or equivalent)

    • Supports research that evaluates orthotic and/or prosthetic devices using patient-centric outcomes relevant to Service members and Veterans with limb loss and/or limb impairment
    • Proposed projects should be designed to provide outcomes data regarding orthotic and/or prosthetic devices and must include the anticipated effect on patient care metrics.
    • Multidisciplinary collaboration among academia, industry, the DoD, the Department of Veterans Affairs (VA), and other Federal Government agencies is highly encouraged.
    • Applications submitted to the FY19 OPORP CRA must address one or more of the FY19 OPORP Focus Areas.
    • Animal studies are not allowed.
    • Clinical trials are not allowed.
    • The FY19 CRA offers two funding levels:

    Funding Level 1:

    ·      Maximum funding of $350,000 for total costs (direct costs plus indirect costs)

    ·      Maximum period of performance is years

    Funding Level 2:

    ·      Maximum funding of $1,000,000 for total costs (direct costs plus indirect costs)

    ·      Maximum period of performance is years

    Clinical Trial Award – Letter of Intent due July 24, 2019

    Independent investigators at all academic levels (or equivalent)

    • Supports rapid implementation of clinical trials with the potential to make significant impacts on improving the health and well-being of Service members, Veterans, and other individuals living with limb deficit.
    • Supports clinical trials that evaluate orthotic and/or prosthetic devices using patient-centric outcomes.
    • Proposed projects should be designed to provide outcomes data regarding orthotic and/or prosthetic devices and must include the anticipated effect on patient care metrics.
    • Multidisciplinary collaboration among academia, industry, the military Services, the VA, and other Federal Government agencies is highly encouraged.
    • Applications submitted to the FY19 OPORP CTA must address one or more of the FY19 OPORP Focus Areas.
    • Preclinical research is not allowed.

    The FY19 CTA offers two funding levels:

    Funding Level 1:

    ·      Maximum funding of $350,000 for total costs (direct costs plus indirect costs)

    ·      Maximum period of performance is years

    Funding Level 2:

    ·      Maximum funding of $2,000,000 for total costs (direct costs plus indirect costs)

    ·      Maximum period of performance is years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the OPORP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 7 Jun 2019 11:09 AM | Hawk Tran (Administrator)

    The FY19 Defense Appropriation provides $20 million (M) to the Department of Defense Joint Program Committee 8/Clinical and Rehabilitative Medicine Research Program (JPC-8/CRMRP) to support the development of regenerative medicine solutions and technical capabilities that repair, reconstruct, or regenerate tissue lost or damage due to traumatic injury through collaborative partnerships and synergistic projects that inform and build on each other.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The JPC-8/CRMRP is offering the Regenerative Medicine Focused Research Award (RMFRA) as its next iteration of the Armed Forces Institute of Regenerative Medicine (AFIRM), AFIRM III, in FY19 to continue its effort to support the development of regenerative medicine solutions.  The JPC-8/CRMRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications for the RMFRA.  The FY19 JPC-8/CRMRP Program Announcement and General Application Instructions for the RMRFA mechanism are anticipated to be posted on the Grants.gov website in June 2019.  Pre-application and application deadlines will be available when the Program Announcement is released.  This pre-announcement should not be construed as an obligation by the government.

    Focus Areas and Areas of Encouragement

    All projects submitted under the FY19 JPC-8/CRMRP RMFRA will be required to address one or both of the following Focus Areas:

    • Peripheral nerve regeneration
    • Skeletal muscle regeneration

    Efforts to regenerate peripheral nerve should focus on restoring maximal function; the goal should be accelerating functional recovery and/or reducing the need for autograft; efforts should not simply address metrics of nerve regrowth or conduits to cross nerve gaps.  Similarly efforts to regenerate skeletal muscle should extend beyond restoration of muscle bulk or structure and address restoration of maximal muscle function.  The FY19 JPC-8/CRMRP RMFRA Areas of Encouragement include:

    • Immediate reconnection of severed peripheral nerves (e.g., preventing Wallerian degeneration)
    • Regeneration of composite muscle and nerve injuries leading to improved function
    • Regenerative therapies for volumetric muscle loss
    • Preservation of denervated end organs
    • Maintenance of the motor end plate or regeneration of the neuromuscular junction
    • Improving the rate of peripheral nerve regeneration

    https://cdmrp.army.mil/pubs/press/2019/19dmrdppreann_jpc8

    Regenerative Medicine Focused Research Award (RMFRA)

    Independent investigators at all academic levels (or equivalent)

    ·      Preproposal is required; full application submission is by invitation only.

    ·      Accommodates either Single Principal Investigator (PI) or Multiple PI submissions.  All research teams should include highly qualified investigators. Partnerships should include multidisciplinary investigators that bring resources and expertise that combine to create a robust, synergistic collaboration.

    ·      Supports the development of regenerative medicine technical capabilities and solutions through collaborative partnerships and synergistic projects (Multiple PI submissions) or through comprehensive projects (Single PI submissions) to accelerate regenerative medicine solutions and technical capabilities that repair, reconstruct, or regenerate tissue lost or damaged due to traumatic injury

    ·      Multi-institutional collaborations between/among academia, industry, and Department of Defense and/or Department of Veterans Affairs facilities are highly encouraged.

    ·      Research projects should be either advanced preclinical research or early stage clinical trials (Phase 0, I, or IIa)

    ·      Applications must address one or both of the FY19 JPC-8/CRMRP RMFRA Focus Areas

    ·     Maximum funding of $10,000,000 for total costs (direct plus indirect costs)

    ·     Submissions may range in size and scope as appropriate for the work proposed, and will be equally considered.  Submissions with a total of less than the maximum  of $10M are encouraged

    ·     Maximum period of performance is 5 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcement and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcement is released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the JPC-8/CRMRP, please visit the CRMRP website (https://crmrp.amedd.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


1717 K ST NW Suite 900

Washington, DC 20006

P: 301-656-5005  |  admin@navref.org

Powered by Wild Apricot Membership Software